Candriam SCA’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Candriam SCA’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-58,427	Closed	-$695K	–	841
2022 Q1	$695K	Hold	58,427	–	–	﹤0.01%	713
2021 Q4	$1.91M	Hold	58,427	–	–	0.01%	553
2021 Q3	$2.61M	Hold	58,427	–	–	0.02%	520
2021 Q2	$3.18M	Buy	+58,427	New	+$3.46M	0.02%	491
2019 Q4	–	Sell	-16,900	Closed	-$1.75M	–	808
2019 Q3	$1.75M	Hold	16,900	–	–	0.02%	517
2019 Q2	$1.56M	Sell	16,900 -3,500	-17%	-$244K	0.02%	568
2019 Q1	$1.86M	Hold	20,400	–	–	0.02%	514
2018 Q4	$1.14M	Hold	20,400	–	–	0.02%	565
2018 Q3	$2.43M	Hold	20,400	–	–	0.03%	459
2018 Q2	$2.08M	Hold	20,400	–	–	0.03%	476
2018 Q1	$2.65M	Sell	20,400 -600	-3%	-$65.6K	0.05%	415
2017 Q4	$2.04M	Buy	21,000 +9,000	+75%	+$1.21M	0.04%	447
2017 Q3	$1.77M	Buy	+12,000	New	+$2.26M	0.03%	480

Other funds holding SYRS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Candriam SCA's SYRS Position: Q2 2022 in Review

Candriam SCA sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2022, closing a stake of 58,427 shares — an estimated $695K sold.

Candriam SCA first reported a position in SYRS in Q3 2017 and held it in 13 quarters. The position peaked at $3.18M in Q2 2021. 67 funds tracked by Wall St. Rank hold SYRS as of Q2 2022.

Candriam SCA reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Candriam SCA sold 58,427 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $695K.
Candriam SCA first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 13 quarters.
Candriam SCA's Syros Pharmaceuticals, Inc. Common Stock position peaked at $3.18M in Q2 2021.
67 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Candriam SCA's 13F filing for Q2 2022, filed 3 Aug 2022.